Binnema D J, Dooijewaard G, Turion P N
Gaubius Institute TNO, Leiden, The Netherlands.
Thromb Haemost. 1991 Feb 12;65(2):144-8.
An analysis was made of the various possible activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction (DEF) of human plasma. scu-PA activators were detected in an assay system in which the substrate scu-PA, in physiological concentration (50 pM), was immuno-immobilized. After activation of the immobilized scu-PA for a certain period of time the activity of the generated amount of immuno-immobilized two-chain u-PA was determined with plasminogen and the chromogenic substrate S-2251. The scu-PA activator activity (scuPA-AA) in the DEF of plasmas deficient in factor XII or prekallikrein was about half of that in the DEF of normal plasma. Separation of scuPA-AA in the DEF by gel chromatography showed to major peaks, one eluting with an apparent Mr of 500,000 and the other around Mr 100,000. The former peak, which coincided with the activity peak of the kallikrein-kininogen complex, was absent in the DEF of plasma depleted of prekallikrein and therefore was identified as kallikrein. The latter peak was still present in the depleted plasma and most likely represents plasmin, because its scuPA-AA coincided with the activity peak of plasmin and could be fully inhibited by antibodies raised against human plasminogen. It is concluded that plasmin and the contact-activation factor kallikrein each contribute for about 50% to the scuPA-AA in the DEF. Compared on a molar basis, however, plasmin was found to be almost 1,000 times more effective than kallikrein, and we conclude, therefore, that in vivo plasmin is the primary activator of scu-PA and the role of the contact system is of secondary importance.
对人血浆硫酸葡聚糖优球蛋白组分(DEF)中各种可能激活单链尿激酶型纤溶酶原激活剂(scu-PA)的物质进行了分析。在一个检测系统中检测到了scu-PA激活剂,该系统中生理浓度(50 pM)的底物scu-PA通过免疫固定化。在将固定化的scu-PA激活一段时间后,用纤溶酶原和发色底物S-2251测定产生的免疫固定化双链u-PA的活性。缺乏因子XII或前激肽释放酶的血浆DEF中的scu-PA激活剂活性(scuPA-AA)约为正常血浆DEF中的一半。通过凝胶色谱法分离DEF中的scuPA-AA显示出两个主要峰,一个以表观Mr为500,000洗脱,另一个在Mr 100,000左右。前一个峰与激肽释放酶-激肽原复合物的活性峰一致,在前激肽释放酶耗尽的血浆DEF中不存在,因此被鉴定为激肽释放酶。后一个峰在耗尽的血浆中仍然存在,很可能代表纤溶酶,因为其scuPA-AA与纤溶酶的活性峰一致,并且可以被抗人纤溶酶原的抗体完全抑制。结论是,纤溶酶和接触激活因子激肽释放酶在DEF中的scuPA-AA中各贡献约50%。然而,以摩尔为基础比较,发现纤溶酶的效力几乎是激肽释放酶的1000倍,因此我们得出结论,在体内纤溶酶是scu-PA的主要激活剂,接触系统的作用是次要的。